Biogen Inc - Company Profile
Powered by 
All the data and insights you need on Biogen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Biogen Inc Strategy Report
- Understand Biogen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreBiogen Inc (Biogen) is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Vumerity (diroximel fumarate), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); Aduhelm (aducanumab-avwa) for Alzheimer’s disease, and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson's disease, Depression, Lupus, CNS and neuromuscular disorders, Amyotrophic Lateral Sclerosis, and Alzheimer’s disease. The company sells its products through a direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
225 Binney Street, Cambridge, Massachusetts, 02142
Website
www.biogen.com
Telephone
1 781 4642000
No of Employees
7,570
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIIB (NASD)
Revenue (2022)
$9.8B
-3.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-61.9%
(2022 vs 2021)
Market Cap*
$28.8B
Net Profit Margin (2022)
XYZ
-60.6%
(2022 vs 2021)
* As of and is in US$
Biogen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Avonex (interferon beta-1a) – Multiple Sclerosis | Alprolix |
| Aduhelm (aducanumab-avwa) - Alzheimer’s Disease | Avonex |
| Fampyra (prolonged-release fampridine tablets) – Multiple Sclerosis | Benepali |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company entered an agreement with AbCellera to identify antibodies for a new target. |
| 2024 | Contracts/Agreements | In March, the company entered an agreement with Indivi to develop digital biomarkers for Parkinson's disease, advancing digital health technology. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with Aptar Digital Health to create digital health solutions for neurological and rare diseases. |
Competitor Comparison
| Key Parameters | Biogen Inc | Bayer AG | Novartis AG | Bristol-Myers Squibb Co | Teva Pharmaceutical Industries Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | Switzerland | United States of America | Israel |
| City | Cambridge | Leverkusen | Basel | Princeton | Tel Aviv |
| State/Province | Massachusetts | Nordrhein-Westfalen | - | New Jersey | Tel Aviv |
| No. of Employees | 7,570 | 99,723 | 76,057 | 34,100 | 35,001 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Caroline Dorsa | Chairman | Executive Board | 2023 | 64 |
| Christopher A. Viehbacher | President; Director; Chief Executive Officer | Executive Board | 2022 | 63 |
| Michael R. McDonnell | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 60 |
| Robin C. Kramer | Senior Vice President; Chief Accounting Officer | Senior Management | 2020 | 58 |
| Susan H. Alexander | Chief Legal Officer; Executive Vice President | Senior Management | 2018 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward